Pathstone Family Office’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Pathstone Family Office’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$900	Hold	10,043	–	–	﹤0.01%	1658
2023 Q2	$924	Hold	10,043	–	–	﹤0.01%	1241
2023 Q1	$2.61K	Sell	10,043 -10,043	-50%	-$2.93K	﹤0.01%	1194
2022 Q4	$70.6K	Sell	20,086 -14	-0.1%	-$4	﹤0.01%	1452
2022 Q3	$5.54K	Buy	20,100 +10,050	+100%	+$4.69K	﹤0.01%	1466
2022 Q2	$7.24K	Hold	10,050	–	–	﹤0.01%	1042
2022 Q1	$8K	Hold	10,050	–	–	﹤0.01%	959
2021 Q4	$10K	Hold	10,050	–	–	﹤0.01%	888
2021 Q3	$17K	Hold	10,050	–	–	﹤0.01%	857
2021 Q2	$18K	Hold	10,050	–	–	﹤0.01%	809
2021 Q1	$20K	Hold	10,050	–	–	﹤0.01%	642
2020 Q4	$22K	Hold	10,050	–	–	﹤0.01%	679
2020 Q3	$28K	Hold	10,050	–	–	﹤0.01%	438
2020 Q2	$39K	Hold	10,050	–	–	﹤0.01%	345
2020 Q1	$8K	Hold	10,050	–	–	﹤0.01%	576
2019 Q4	$127K	Buy	10,050 +2,525	+34%	+$2.18K	﹤0.01%	414
2019 Q3	$5K	Hold	7,525	–	–	﹤0.01%	541
2019 Q2	$5K	Hold	7,525	–	–	﹤0.01%	565
2019 Q1	$21K	Buy	+7,525	New	+$22.2K	﹤0.01%	429

Other funds holding NAVB

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFAS

Level Four Advisory Services Dallas, Texas $3.05B AUM 23.96% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Pathstone Family Office's NAVB Position: Q3 2023 in Review

Pathstone Family Office held its Navidea Biopharmaceuticals Inc. (NAVB) position steady in Q3 2023 at 10,043 shares worth $900. The position accounts for ﹤0.01% of the portfolio, ranked #1658.

Pathstone Family Office first reported a position in NAVB in Q1 2019 and has held it in 19 quarters since. The position peaked at $127K in Q4 2019. 24 funds tracked by Wall St. Rank hold NAVB as of Q3 2023.

Pathstone Family Office held 10,043 shares of Navidea Biopharmaceuticals Inc. worth $900 as of Q3 2023.
Pathstone Family Office left its Navidea Biopharmaceuticals Inc. share count unchanged in Q3 2023.
Navidea Biopharmaceuticals Inc. made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1658 holding.
Pathstone Family Office first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2019 and has held it in 19 quarters since.
Pathstone Family Office's Navidea Biopharmaceuticals Inc. position peaked at $127K in Q4 2019.
24 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.